Importantly, these interactions occur in primary AML cells but not in their normal counterparts, and the Src/MCL-1 antagonist strategy is well tolerated and effective in multiple xenograft and PDX AML models. The gene discussed is MCL1; the disease is acute myeloid leukemia.